Clinical Trial Update: Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery [Phase 4]

View source ↗

Summary

Phase 4 clinical trial sponsored by Mayo Clinic evaluating a uroselective alpha-1 antagonist to reduce the incidence and duration of postoperative urinary reten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Retention

Snippet

Sponsor: Mayo Clinic | Conditions: Urinary Retention Postoperative | Phase 4 | Status: RECRUITING